期刊文献+

帕金森病脑功能网络的影像学研究进展 被引量:4

原文传递
导出
摘要 帕金森病(Parkinson’s disease,PD)是一种致残度极高的中老年神经系统变性疾病。由于发达国家和中国等部分发展中国家人口老龄化,PD的发病率显著上升,给家庭和社会都造成了极大的负面影响,受到社会各界的重视。近年来,国内外学者利用MRI、磁共振功能成像(fMRI)、磁共振波谱成像(MRS)、PET、脑电图(EEG)、脑磁图(MEG)等影像技术,以脑功能网络为着眼点,研究PD的发病机制,取得了丰富的研究成果,现综述如下。
作者 颜莉蓉
出处 《中华神经科杂志》 CAS CSCD 北大核心 2011年第12期857-859,共3页 Chinese Journal of Neurology
基金 国家自然科学基金资助项目(30800253)
  • 相关文献

参考文献35

  • 1马建芳,吴逸雯,陈晟,肖勤,陈生弟.第18届世界神经病学联盟帕金森病及相关疾病学术会议纪要[J].中华神经科杂志,2010,43(4):303-305. 被引量:2
  • 2Mclntosh AR.Mapping cognition to the brain through neural interactions.Memory,1999,7:523-548.
  • 3Friston KJ.Functional and effective connectivity in neuroimaging:a synthesis.Hum Brain Mapp,1994,2:56-78.
  • 4Friston KJ,Harrison L,Penny W.Dynamic causal modeling.NeuroImage,2003,19:1273-1302.
  • 5Alexander GE,Moeller JR.Application of the scaled subprofile model to functional imaging in neuropsychiatric disorders:a principal component approach to modeling brain function in disease.Hum Brain Mapp,1994,2:1-16.
  • 6Eidelberg D.Metabolic brain networks in neurodegenerative disorders:a functional imaging approach.Trends Neurosci,2009,32:548-557.
  • 7Eckert T,Laere KV,Tang C,et al.Quantification of Parkinson' s disease-related network expression with ECD SPECT.Eur J Nucl Med Mol Imaging,2007,34:496-501.
  • 8Helmich RC,Derikx LC,Bakker M,et al.Spatial remapping of cortico-striatal connectivity in Parkinson' s disease.Cereb Cortex,2010,20:1175-1186.
  • 9Kwak Y,Peltier S,Bohnen NI,et al.Altered resting state cortico-striatal connectivity in mild to moderate stage Parkinson' s disease.Front Syst Neurosci,2010,4:1-25.
  • 10Rowe J,Stephan KE,Friston K J,et al.Attention to action in Parkinson' s disease:impaired effective connectivity among frontal cortical regions.Brain,2002,125:276-289.

二级参考文献53

  • 1蒋雨平,王坚,丁正同,管一晖,赵军,陈正平,项景德,苏惠琳.^(18)F-FP-CIT PET和^(99)Tc^m-TRODAT-1 SPECT纹状体DAT显像在早期诊断帕金森病中的敏感性比较[J].中国临床神经科学,2006,14(2):128-133. 被引量:4
  • 2Brooks DJ,Frey KA,Marek KL,et al.Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease.Exp Neural,2003,184 Suppl 1:S68-79.
  • 3Dabwan V,Ma Y,Pillai V,et al.Comparative analysis of striatal FDOPA uptake in Parkinson' s disease:ratio method versus graphical approach.J Nucl Med,2002,43:1324-1330.
  • 4Eshuis SA,Jager PL,Maguire RP,et al.Direct comparison of FP-CIT SPECT and F-DOPA PET in patients with Parkinson' s disease and healthy controls.Eur J Nucl Med Mol Imaging,2009,36:454-462.
  • 5Malter W,Liepelt I,Berg D.Progression of Parkinson' s disease in the clinical phase:potential markers.Lancet Neural,2009,8:1158-1171.
  • 6Breit S,Reimold M,Reischl G,et al.11C d-threomethylphenidate PET in patients with Parkinson' s disease and essential tremor.J Neural Transm,2006,113:187-193.
  • 7Zijlmans J,Evans A,Fonts F,et al.123I FP-CIT spect study in vascular parkinsonism and Parkinson' s disease.Mov Disord,2007,22:1278-1285.
  • 8Stoffers D,Booij J,Bosscher L,et al.Early-stage 123I beta-CIT SPECT and long-term clinical follow-up in patients with an initial diagnosis of Parkinson' s disease.Eur J Nucl Med Mol Imaging,2005,32:689-695.
  • 9Seppi K,Scherfler C,Donnemiller E,et al.Topography of dopamine transporter availability in progressive supranuclear palsy:a voxelwise 123I beta-CIT SPECT analysis.Arch Neurol,2006,63:1154-1160.
  • 10Parkinson Study Group.A multicenter assessment of dopamine transporter imaging with DOPASCAN/SPECT in parkinsonism.Neurology,2000,55:1540-1547.

共引文献3

同被引文献90

  • 1Stoessl A J, Brooks DJ, Eidelberg D. Milestones in neumimaging. Mov Disord, 2011, 26: 868-978.
  • 2Hughes A J, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson' s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry, 1992, 55: 181-184.
  • 3Hughes AJ, Daniel SE, Lees AJ. diagnosis of Lewy body Parkinson 57 : 1497-1499.
  • 4Improved accuracy of clinical s disease. Neurology, 2001, Hughes AJ, Daniel SE, Ben-Shlomo Y, et al. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain, 2002, 125 Pt 4: 861-870.
  • 5Morfish PK, Rakshi JS, Bailey DL, et al. Measuring the rate of progression and estimating the preclinical period of Parkinson' s disease with [ lS Fl dopa PET. J Neurol Neurosurg Psychiatry, 1998, 64: 314-319.
  • 6Eckert T, Tang C, Eidelberg D. Assessment of the progression of Parkinson' s disease: a metabolic network approach. Lancet Neurol, 2007, 6: 926-932.
  • 7Prakash KM, Tan EK. Development of Parkinson' s disease biomarkers. Expert Rev Neurother, 2010, l0 : 1811-1825.
  • 8Tatsch K. Positron emission tomography in diagnosis and differential diagnosis of Parkinson' s disease. Neurodegener Dis, 2010, 7: 330-340.
  • 9Au WL, Adams JR, Troiano AR, et al. Parkinson' s disease : in vivo assessment of disease progression using positron emission tomography. Brain Res Mol Brain Res, 2005, 134: 24-33.
  • 10Wang J, Zuo CT, Jiang YP, et al. ~SF-FP-CIT PET imaging and SPM analysis of dopamine transporters in Parkinson' s disease in various Hoehn&Yahr stages. J Neurol, 2007, 254: 185-190.

引证文献4

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部